REV PRO 32

REVS

Aesthetic injectable

Skin booster / bioremodeller (hyaluronic acid)

Marketed as an injectable hyaluronic acid skin booster/bioremodeller rather than as a licensed medicinal product; no UK MHRA medicinal marketing authorisation identified for REV PRO 32 / REVS PRO32.
Typically classified and supplied as a medical device or aesthetic injectable skin booster in distributor catalogues, subject to local device regulations.
Some manufacturing and wholesale sources reference CE and ISO certification for the product or its production, but detailed certificate numbers and classifications are not consistently disclosed in public listings.
Must be used by qualified healthcare/aesthetic professionals in line with local regulatory requirements for injectable HA devices and cosmetic procedures.

Marketed as an injectable hyaluronic acid skin booster/bioremodeller rather than as a licensed medicinal product; no UK MHRA medicinal marketing authorisation identified for REV PRO 32 / REVS PRO32.
Typically classified and supplied as a medical device or aesthetic injectable skin booster in distributor catalogues, subject to local device regulations.
Some manufacturing and wholesale sources reference CE and ISO certification for the product or its production, but detailed certificate numbers and classifications are not consistently disclosed in public listings.
Must be used by qualified healthcare/aesthetic professionals in line with local regulatory requirements for injectable HA devices and cosmetic procedures.

Skin booster / bioremodeller (hyaluronic acid)

Description

REV PRO 32 (REVS PRO32) is an injectable hybrid skin booster containing a total of 64 mg stabilised hyaluronic acid (HA) in a 2 ml prefilled syringe. The formulation combines 32 mg high molecular weight HA (H-HA) and 32 mg low molecular weight HA (L-HA), providing 32 mg HA per ml. It is intended for skin remodelling and treatment of skin laxity, delivering intensive hydration, bio-revitalisation and improvement of tissue quality rather than simply filling individual lines and wrinkles. The product is typically used on areas affected by laxity such as the malar and submalar regions and other facial areas, and is positioned as a Profhilo-strength alternative skin booster. Pack contains 1 x 2 ml syringe; needles are not included and must be supplied separately.

Bnefits

High HA concentration (64 mg per 2 ml) for powerful hydration and dermal bio-revitalisation.
Hybrid formulation of high and low molecular weight hyaluronic acid to target multiple skin layers.
Intended for skin remodelling and improvement of skin laxity, not just line or wrinkle filling.
Improves tissue quality, skin firmness and elasticity in challenging areas.
Provides deep, long-lasting hydration with visible improvement in skin texture and radiance.
Complementary to other aesthetic treatments and dermal filler procedures (used alongside, not instead of, structural fillers).

Indications

Injectable skin booster treatment for photo-aged, dehydrated or lax facial skin in adults, performed by suitably qualified healthcare professionals.
Skin remodelling and treatment of mild to moderate skin laxity, especially in the malar and submalar areas and other facial zones.
Improvement of dermal hydration, elasticity and overall skin quality where injectable HA skin boosters are appropriate.
Adjunctive treatment to complement other aesthetic procedures such as dermal fillers, toxins or energy-based devices as part of a broader rejuvenation plan.

Composition

Hyaluronic acid (HA) 64 mg per 2 ml (32 mg high molecular weight HA and 32 mg low molecular weight HA).
Stabilised, non-cross-linked hybrid hyaluronic acid (H-HA and L-HA) designed for skin remodelling.
Buffering/excipient solution (e.g. phosphate-buffered saline and standard excipients suitable for injectable HA; exact excipient list not publicly detailed).
Sterile, pyrogen-free, colourless, viscoelastic HA gel intended for injection by a medical professional.

Formulation

Sterile, stabilised, non-cross-linked hyaluronic acid gel (hybrid high and low molecular weight HA).
Concentration: 32 mg HA per ml (64 mg in 2 ml).
Presentation: 1 x 2 ml prefilled glass syringe with luer connection (needles supplied separately by clinic).
Intended for intradermal or superficial/subdermal injection for skin remodelling and hydration.

Packaging

Box containing 1 prefilled syringe x 2 ml REVS PRO32 (REV PRO 32).
Needles are not included in the pack and must be sourced separately (typically 29–32G mesotherapy or injection needles as per clinic protocol).
Each syringe is supplied in a sterile blister or tray with tamper-evident packaging and product labelling.
Outer carton includes basic product information, batch/lot number and expiry date.

Usage

For professional use only; REV PRO 32 must be injected exclusively by suitably trained and qualified healthcare or aesthetic practitioners in accordance with local regulations.
Typical treatment indication is skin remodelling and improvement of skin laxity in the face (especially malar and submalar regions); injection depth and technique should follow the manufacturer’s guidelines and the practitioner’s clinical judgement.
Commonly used techniques include a 5-point injection protocol per side of the face or multiple micro-injections over the treatment area using fine gauge needles (for example 29–32G).
The product is injected into the deep dermis or superficial subcutaneous layer depending on the chosen technique and anatomical site.
Standard protocols often recommend an initial course of at least 2–3 treatment sessions spaced roughly 4 weeks apart, with maintenance sessions at intervals determined by the clinician (for many patients, results may last around 6–9 months, subject to age, skin condition and lifestyle).
Do not inject into blood vessels, very superficial epidermis or directly into or near inflammatory lesions, active infections or tumours.
As with any injectable HA treatment, strict aseptic technique must be observed, and appropriate pre-treatment assessment, informed consent and post-procedure care should be provided.
After treatment, patients should follow their practitioner’s aftercare instructions (for example, avoiding makeup, heat exposure, vigorous exercise or massage of the treated area for a specified period, and monitoring for any adverse reactions).

Contraindications

Known hypersensitivity or allergy to hyaluronic acid or any of the excipients.
Active skin infections, inflammation or disease at or near the intended injection sites (e.g. herpes simplex, bacterial or fungal infections, dermatitis).
History of severe allergic reactions or anaphylaxis to injectable products, unless fully assessed and cleared by a suitably qualified clinician.
Autoimmune diseases or immunocompromised states, unless the treating physician considers treatment appropriate and safe.
Pregnancy and breastfeeding, as safety for these groups has not been established.
Bleeding disorders, current use of significant anticoagulant or antiplatelet medication, or other conditions that increase the risk of bruising or bleeding, unless carefully evaluated by a medical professional.
Previous hypersensitivity or adverse reaction to another injectable skin booster or dermal filler where cross-reactivity with HA formulations is a concern.
Use in patients under the legal age of consent for aesthetic injectable treatments in the relevant jurisdiction.

Adverse Effects

Common, usually transient injection-site reactions such as redness (erythema), swelling, tenderness, itching, discomfort or mild pain.
Bruising or haematoma formation at injection sites, particularly in patients prone to bruising or on anticoagulant/antiplatelet therapy.
Temporary lumps, nodules or unevenness at the injection area, which usually resolve as the product integrates; persistent nodules require clinical review.
Rare but potentially serious events associated with injectable HA products, including infection, abscess, allergic or hypersensitivity reactions and, in extremely rare cases, vascular occlusion if inadvertently injected into or compressed against a blood vessel.
Post-treatment flare of pre-existing inflammatory skin conditions near the injection area in susceptible individuals.
Very rarely, delayed inflammatory reactions or granuloma formation can occur and require medical management.

Storage Conditions

Store in accordance with the product carton instructions, typically in a cool, dry place at controlled room temperature (commonly between 2°C and 25°C); do not freeze.
Keep the syringe in its original outer packaging to protect it from light and physical damage until use.
Do not use the product after the expiry date printed on the packaging.
Do not use if the blister or outer packaging is damaged, the syringe appears compromised, or the solution is discoloured or contains visible particulates.
Single-use only; once the syringe has been used for a treatment, any remaining product must be discarded and not reused.
Store out of the reach and sight of unauthorised persons and children.

Duration

Initial treatment is typically carried out over 2\u20133 sessions spaced about 4 weeks apart, with effects often maintained for approximately 6\u20139 months or longer depending on individual factors; maintenance or repeat courses are scheduled according to clinical assessment and patient goals.

Onset

Improvement in hydration and skin glow may be visible within days to a few weeks after treatment, with further improvements in elasticity, firmness and texture developing progressively over subsequent weeks following the initial treatment sessions.